Skip to main navigation Skip to search Skip to main content

Tumor suppressors in acute myeloid leukemia

Research output: Journal article (peer-reviewed)Review article

Abstract

Acute myeloid leukemia (AML) is a very heterogeneous type of blood cancer, which presents with a high rate of mortality especially in elderly patients. Better understanding of critical players, such as molecules with tumor suppressive properties, may help to fine-tune disease classification and thereby treatment modalities for this detrimental disease. Here, we summarize well-known and established tumor suppressors as well as emerging tumor suppressors, including transcription factors (TCFs) and other transcriptional regulators, such as epigenetic modulators. In addition, we look into the versatile field of miRNAs also interfering with tumorigenesis and progression, which offer new possibilities in AML diagnosis, prognosis, and therapy.

Original languageEnglish
Pages (from-to)2320-2330
Number of pages11
JournalLeukemia and Lymphoma
Volume62
Issue number10
DOIs
Publication statusPublished - Oct 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Aged
  • Carcinogenesis
  • Cell Transformation, Neoplastic
  • Humans
  • Leukemia, Myeloid, Acute/diagnosis
  • MicroRNAs/genetics
  • Prognosis
  • transcription factor
  • epigenetic regulator
  • miRNA
  • tumor suppressor
  • Acute myeloid leukemia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Tumor suppressors in acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this